ABSTRACT
The new 2-aminomethylphenol, JPC-3210, has potent in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, low cytotoxicity, and high in vivo efficacy against murine malaria. Here we report on the pharmacokinetics of JPC-3210 in mice and monkeys and the results of in vitro screening assays, including the inhibition of cytochrome P450 (CYP450) isozymes. In mice, JPC-3210 was rapidly absorbed and had an extensive tissue distribution, with a brain tissue-to-plasma concentration ratio of about 5.4. JPC-3210 had a lengthy plasma elimination half-life of about 4.5 days in mice and 11.8 days in monkeys. JPC-3210 exhibited linear single-oral-dose pharmacokinetics across the dose range of 5 to 40 mg/kg of body weight with high oral bioavailability (â¼86%) in mice. Systemic blood exposure of JPC-3210 was 16.6% higher in P. berghei-infected mice than in healthy mice. In vitro studies with mice and human hepatocytes revealed little metabolism and the high metabolic stability of JPC-3210. The abundance of human metabolites from oxidation and glucuronidation was 2.0% and 2.5%, respectively. CYP450 studies in human liver microsomes showed JPC-3210 to be an inhibitor of CYP2D6 and, to a lesser extent, CYP3A4 isozymes, suggesting the possibility of a metabolic drug-drug interaction with drugs that are metabolized by these isozymes. In vitro studies showed that JPC-3210 is highly protein bound to human plasma (97%). These desirable pharmacological findings of a lengthy blood elimination half-life, high oral bioavailability, and low metabolism as well as high in vivo potency have led the Medicines for Malaria Venture to select JPC-3210 (MMV892646) for further advanced preclinical development.
Subject(s)
Antimalarials/therapeutic use , Malaria/drug therapy , Malaria/prevention & control , Animals , Antimalarials/chemistry , Cells, Cultured , Cytochrome P-450 Enzyme System/metabolism , Drug Resistance, Multiple , Female , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Male , Mice , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Protein Binding , RatsABSTRACT
The host employs both cell-autonomous and system-level responses to limit pathogen replication in the initial stages of infection. Previously, we reported that the eukaryotic initiation factor 2α (eIF2α) kinases heme-regulated inhibitor (HRI) and protein kinase R (PKR) control distinct cellular and immune-related activities in response to diverse bacterial pathogens. Specifically for Listeria monocytogenes, there was reduced translocation of the pathogen to the cytosolic compartment in HRI-deficient cells and consequently reduced loading of pathogen-derived antigens on major histocompatibility complex class I (MHC-I) complexes. Here we show that Hri-/- mice, as well as wild-type mice treated with an HRI inhibitor, are more susceptible to listeriosis. In the first few hours of L. monocytogenes infection, there was much greater pathogen proliferation in the liver of Hri-/- mice than in the liver of Hri+/+ mice. Further, there was a rapid increase of serum interleukin-6 (IL-6) levels in Hri+/+ mice in the first few hours of infection whereas the increase in IL-6 levels in Hri-/- mice was notably delayed. Consistent with these in vivo findings, the rate of listeriolysin O (LLO)-dependent pathogen efflux from infected Hri-/- macrophages and fibroblasts was significantly higher than the rate seen with infected Hri+/+ cells. Treatment of cells with an eIF2α kinase activator enhanced both the HRI-dependent and PKR-dependent infection phenotypes, further indicating the pharmacologically malleability of this signaling pathway. Collectively, these results suggest that HRI mediates the cellular confinement and killing of virulent L. monocytogenes in addition to promoting a system-level cytokine response and that both are required to limit pathogen replication during the first few hours of infection.
Subject(s)
Listeria monocytogenes/physiology , Listeriosis/enzymology , Protein Serine-Threonine Kinases/immunology , Animals , Female , Humans , Interleukin-6/genetics , Interleukin-6/metabolism , Listeria monocytogenes/genetics , Listeriosis/genetics , Listeriosis/immunology , Listeriosis/microbiology , Macrophages/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Phosphorylation , Protein Serine-Threonine Kinases/geneticsABSTRACT
Structure-activity relationship studies of trifluoromethyl-substituted pyridine and pyrimidine analogues of 2-aminomethylphenols (JPC-2997, JPC-3186, and JPC-3210) were conducted for preclinical development for malaria treatment and/or prevention. Of these compounds, JPC-3210 [4-(tert-butyl)-2-((tert-butylamino)methyl)-6-(5-fluoro-6-(trifluoromethyl)pyridin-3-yl)phenol] was selected as the lead compound due to superior in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, lower in vitro cytotoxicity in mammalian cell lines, longer plasma elimination half-life, and greater in vivo efficacy against murine malaria.
Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Malaria/drug therapy , Phenols/therapeutic use , Animals , Cell Line , Cricetinae , HEK293 Cells , Hep G2 Cells , Humans , Mefloquine/therapeutic use , Mice , Plasmodium falciparum/drug effects , Plasmodium falciparum/pathogenicity , Pyridines/therapeutic useABSTRACT
4-(tert-Butyl)-2-((tert-butylamino)methyl)-6-(6-(trifluoromethyl)pyridin-3-yl)-phenol (JPC-2997) is a new aminomethylphenol compound that is highly active in vitro against the chloroquine-sensitive D6, the chloroquine-resistant W2, and the multidrug-resistant TM90-C2B Plasmodium falciparum lines, with 50% inhibitory concentrations (IC50s) ranging from 7 nM to 34 nM. JPC-2997 is >2,500 times less cytotoxic (IC50s > 35 µM) to human (HepG2 and HEK293) and rodent (BHK) cell lines than the D6 parasite line. In comparison to the chemically related WR-194,965, a drug that had advanced to clinical studies, JPC-2997 was 2-fold more active in vitro against P. falciparum lines and 3-fold less cytotoxic. The compound possesses potent in vivo suppression activity against Plasmodium berghei, with a 50% effective dose (ED50) of 0.5 mg/kg of body weight/day following oral dosing in the Peters 4-day test. The radical curative dose of JPC-2997 was remarkably low, at a total dose of 24 mg/kg, using the modified Thompson test. JPC-2997 was effective in curing three Aotus monkeys infected with a chloroquine- and pyrimethamine-resistant strain of Plasmodium vivax at a dose of 20 mg/kg daily for 3 days. At the doses administered, JPC-2997 appeared to be well tolerated in mice and monkeys. Preliminary studies of JPC-2997 in mice show linear pharmacokinetics over the range 2.5 to 40 mg/kg, a low clearance of 0.22 liters/h/kg, a volume of distribution of 15.6 liters/kg, and an elimination half-life of 49.8 h. The high in vivo potency data and lengthy elimination half-life of JPC-2997 suggest that it is worthy of further preclinical assessment as a partner drug.
Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Phenols/therapeutic use , Plasmodium falciparum/drug effects , Pyridines/therapeutic use , Animals , Antimalarials/adverse effects , Antimalarials/pharmacokinetics , Aotidae , Cell Line , Cricetinae , Drug Resistance , HEK293 Cells , Hep G2 Cells , Humans , Mice , Parasitic Sensitivity Tests , Phenols/adverse effects , Phenols/pharmacokinetics , Plasmodium berghei/drug effects , Plasmodium vivax/drug effects , Pyridines/adverse effects , Pyridines/pharmacokineticsABSTRACT
BACKGROUND: Amphotericin B (AmB), the most effective drug against leishmaniasis, has serious toxicity. As Leishmania species are obligate intracellular parasites of antigen presenting cells (APC), an immunopotentiating APC-specific AmB nanocarrier would be ideally suited to reduce the drug dosage and regimen requirements in leishmaniasis treatment. Here, we report a nanocarrier that results in effective treatment shortening of cutaneous leishmaniasis in a mouse model, while also enhancing L. major specific T-cell immune responses in the infected host. METHODS: We used a Pan-DR-binding epitope (PADRE)-derivatized-dendrimer (PDD), complexed with liposomal amphotericin B (LAmB) in an L. major mouse model and analyzed the therapeutic efficacy of low-dose PDD/LAmB vs full dose LAmB. RESULTS: PDD was shown to escort LAmB to APCs in vivo, enhanced the drug efficacy by 83% and drug APC targeting by 10-fold and significantly reduced parasite burden and toxicity. Fortuitously, the PDD immunopotentiating effect significantly enhanced parasite-specific T-cell responses in immunocompetent infected mice. CONCLUSIONS: PDD reduced the effective dose and toxicity of LAmB and resulted in elicitation of strong parasite specific T-cell responses. A reduced effective therapeutic dose was achieved by selective LAmB delivery to APC, bypassing bystander cells, reducing toxicity and inducing antiparasite immunity.
Subject(s)
Amphotericin B/administration & dosage , Antiprotozoal Agents/administration & dosage , Dendrimers/administration & dosage , Leishmania major/drug effects , Leishmaniasis, Cutaneous/drug therapy , Malaria Vaccines/administration & dosage , Adaptive Immunity , Amphotericin B/toxicity , Animals , Antigen-Presenting Cells/immunology , Antiprotozoal Agents/toxicity , Disease Models, Animal , Drug Carriers , Epitopes , Female , Injections, Intraperitoneal , Leishmania major/immunology , Leishmaniasis Vaccines , Leishmaniasis, Cutaneous/immunology , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Microscopy, Electron, Transmission , NanoparticlesABSTRACT
Exploration of triclosan analogs has led to novel diaryl ureas with significant potency against in vitro cultures of drug-resistant and drug-sensitive strains of the human malaria parasite Plasmodium falciparum. Compound 18 demonstrated EC(50) values of 37 and 55 nM versus in vitro cultured parasite strains and promising in vivo efficacy in a Plasmodium berghei antimalarial mouse model, with >50% survival at day 31 post-treatment when administered subcutaneously at 256 mg/kg. This series of compounds provides a chemical scaffold of novel architecture, as validated by cheminformatics analysis, to pursue antimalarial drug discovery efforts.
Subject(s)
Antimalarials/pharmacology , Benzene Derivatives/pharmacology , Malaria, Falciparum/drug therapy , Urea/analogs & derivatives , Urea/pharmacology , Animals , Antimalarials/chemistry , Benzene Derivatives/chemistry , Disease Models, Animal , Drug Discovery , Malaria, Falciparum/parasitology , MiceABSTRACT
Novel classes of antimalarial drugs are needed due to emerging drug resistance. Azithromycin, the first macrolide investigated for malaria treatment and prophylaxis, failed as a single agent and thus novel analogues were envisaged as the next generation with improved activity. We synthesized 42 new 9a-N substituted 15-membered azalides with amide and amine functionalities via simple and inexpensive chemical procedures using easily available building blocks. These compounds exhibited marked advances over azithromycin in vitro in terms of potency against Plasmodium falciparum (over 100-fold) and high selectivity for the parasite and were characterized by moderate oral bioavailability in vivo. Two amines and one amide derivative showed improved in vivo potency in comparison to azithromycin when tested in a mouse efficacy model. Results obtained for compound 6u, including improved in vitro potency, good pharmacokinetic parameters, and in vivo efficacy higher than azithromycin and comparable to chloroquine, warrant its further development for malaria treatment and prophylaxis.
Subject(s)
Aminoquinolines/chemical synthesis , Antimalarials/chemical synthesis , Erythromycin/analogs & derivatives , Macrolides/chemical synthesis , Amides/chemical synthesis , Amides/pharmacokinetics , Amides/pharmacology , Amines/chemical synthesis , Amines/pharmacokinetics , Amines/pharmacology , Aminoquinolines/pharmacokinetics , Aminoquinolines/pharmacology , Animals , Antimalarials/pharmacokinetics , Antimalarials/pharmacology , Azithromycin/pharmacology , Cell Line, Tumor , Drug Resistance , Erythromycin/chemical synthesis , Erythromycin/pharmacokinetics , Erythromycin/pharmacology , Humans , Macrolides/pharmacokinetics , Macrolides/pharmacology , Malaria/drug therapy , Male , Mice , Microsomes, Liver/metabolism , Parasitic Sensitivity Tests , Plasmodium berghei , Plasmodium falciparum/drug effects , Rats , Structure-Activity RelationshipABSTRACT
Azithromycin, a first member of the azalide family of macrolides, while having substantial antimalarial activity, failed as a single agent for malaria prophylaxis. In this paper we present the first analogue campaign to identify more potent compounds from this class. Ureas and thioureas of 15-membered azalides, N''-substituted 9a-(N'-carbamoyl-ß-aminoethyl), 9a-(N'-thiocarbamoyl-ß-aminoethyl), 9a-[N'-(ß-cyanoethyl)-N'-(carbamoyl-ß-aminoethyl)], 9a-[N'-(ß-cyanoethyl)-N'-(thiocarbamoyl-ß-aminoethyl)], 9a-{N'-[ß-(ethoxycarbonyl)ethyl]-N'(carbamoyl-ß-aminoethyl)}, and 9a-[N'-(ß-amidoethyl)-N'-(carbamoyl-ß-aminoethyl)] of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A, were synthesized and their biological properties evaluated. The results obtained indicate a substantial improvement of the in vitro activity against P. falciparum (up to 88 times over azithromycin), particularly for compounds containing both sugars on the macrocyclic ring and aromatic moiety on 9a-position. The improved in vitro activity was not confirmed in the mouse model, likely due to an increase in lipophilicity of these analogues leading to a higher volume of distribution. Overall, with increased in vitro activity, promising PK properties, and modest in vivo efficacy, this series of molecules represents a good starting platform for the design of novel antimalarial azalides.
Subject(s)
Antimalarials/chemical synthesis , Macrolides/chemistry , Thiourea/chemistry , Urea/chemistry , Animals , Antimalarials/chemistry , Azithromycin/analogs & derivatives , Chemistry, Pharmaceutical/methods , Drug Design , Humans , Inhibitory Concentration 50 , Mice , Models, Chemical , Plasmodium falciparum/metabolism , Structure-Activity RelationshipABSTRACT
The fatty acid synthesis type II pathway has received considerable interest as a candidate therapeutic target in Plasmodium falciparum asexual blood-stage infections. This apicoplast-resident pathway, distinct from the mammalian type I process, includes FabI. Here, we report synthetic chemistry and transfection studies concluding that Plasmodium FabI is not the target of the antimalarial activity of triclosan, an inhibitor of bacterial FabI. Disruption of fabI in P. falciparum or the rodent parasite P. berghei does not impede blood-stage growth. In contrast, mosquito-derived, FabI-deficient P. berghei sporozoites are markedly less infective for mice and typically fail to complete liver-stage development in vitro. This defect is characterized by an inability to form intrahepatic merosomes that normally initiate blood-stage infections. These data illuminate key differences between liver- and blood-stage parasites in their requirements for host versus de novo synthesized fatty acids, and create new prospects for stage-specific antimalarial interventions.
Subject(s)
Liver/parasitology , Plasmodium berghei/pathogenicity , Plasmodium falciparum/pathogenicity , Protozoan Proteins/metabolism , Animals , Antimalarials/pharmacology , Gene Deletion , Malaria/parasitology , Mice , Mice, Inbred C57BL , Mutagenesis, Insertional , Parasitemia , Plasmodium berghei/enzymology , Plasmodium berghei/growth & development , Plasmodium falciparum/enzymology , Plasmodium falciparum/growth & development , Protozoan Proteins/genetics , Triclosan/pharmacologyABSTRACT
8-Aminoquinolines are an important class of antiparasitic agents, with broad utility and excellent efficacy, but also limitations due to hematological toxicities, primarily methemoglobinemia and hemolysis. One representative from this class, (+/-)-8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate (NPC1161C), proved extremely efficacious in animal models of malaria and pneumocystis pneumonia. This racemic mixture was separated into its component enantiomers by chemical and chromatographic means. The enantiomers were evaluated for antiparasitic activity in murine models of Plasmodium berghei, Pneumocystis carinii, and Leishmania donovani infection, as well as the propensity to elicit hematotoxicity in dogs. The (-)-enantiomer NPC1161B was found to be more active (by severalfold, depending on the dosing regimen) than the (+)-enantiomer NPC1161A in all of these murine models. In addition, the (-) enantiomer showed markedly reduced general toxicity in mice and reduced hematotoxicity in the dog model of methemoglobinemia. It is concluded that the configuration at the asymmetric center in the 8-amino side chain differentially affects efficacy and toxicity profiles and thus may be an important determinant of the "therapeutic window" for compounds in this class.
Subject(s)
Aminoquinolines , Antifungal Agents/pharmacology , Antiprotozoal Agents/pharmacology , Leishmania donovani/drug effects , Plasmodium berghei/drug effects , Pneumocystis carinii/drug effects , Aminoquinolines/chemistry , Aminoquinolines/pharmacology , Aminoquinolines/therapeutic use , Aminoquinolines/toxicity , Animals , Antifungal Agents/chemistry , Antifungal Agents/toxicity , Antiprotozoal Agents/chemistry , Antiprotozoal Agents/toxicity , Dogs , Female , Hemolysis , Humans , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/parasitology , Malaria/drug therapy , Malaria/parasitology , Male , Methemoglobinemia/etiology , Mice , Mice, Inbred BALB C , Pneumonia, Pneumocystis/drug therapy , Pneumonia, Pneumocystis/microbiology , Stereoisomerism , Structure-Activity RelationshipABSTRACT
A series of acid-stable carboxamide derivatives of 2-guanidinoimidazolidinedione (5a-c and 6a-c) were prepared as potential malaria prophylactic and radical cure agents. The new compounds showed moderate to good causal prophylactic activity in mice infected with Plasmodium yoelii sporozoites. Three compounds were further tested for causal prophylactic activity in Rhesus monkeys infected with Plasmodium cynomolgi sporozoites, and all showed a delay in patency from 13 to 40 days at 30 mg/kg/day x 3 days by IM dosing. Two out of four compounds tested for radical curative activity in Rhesus showed cure at 30 mg/kg/day x 3 days. The other two compounds showed delay in relapse from 16 to 68 days. Conversion of new carboxamides (5 and 6) to s-triazine derivatives (7) was demonstrated in mouse and human microsomal preparations and in rat plasma. The results suggest the metabolites, s-triazine derivatives 7, may be the active species of the new carboxamides 5a-c and 6a-c prepared in this study.
Subject(s)
Antimalarials/chemical synthesis , Guanidines/chemical synthesis , Imidazolidines/chemical synthesis , Malaria/drug therapy , Malaria/prevention & control , Animals , Antimalarials/chemistry , Antimalarials/pharmacology , Guanidines/chemistry , Guanidines/pharmacology , Humans , Imidazolidines/chemistry , Imidazolidines/pharmacology , In Vitro Techniques , Mice , Microsomes, Liver/metabolism , Plasmodium cynomolgi/drug effects , Plasmodium yoelii/drug effects , Rats , Structure-Activity RelationshipABSTRACT
OBJECTIVES: To assess the antimalarial pharmacodynamics and pharmacokinetics of the novel dihydrofolate reductase (DHFR) inhibitor, JPC2056 and its principal active metabolite JPC2067 in cynomolgus monkeys using an in vivo-in vitro model. METHODS: In a two-phase crossover design, five cynomolgus monkeys were administered a single dose (20 mg/kg) and multiple doses (20 mg/kg daily for 3 days) of JPC2056. Plasma samples collected from treated monkeys were assessed for in vitro antimalarial activity against Plasmodium falciparum lines having wild-type (D6), double-mutant (K1) and quadruple-mutant (TM90-C2A) DHFR-thymidylate synthase (TS) and a P. falciparum line transformed with a Plasmodium vivax dhfr-ts quadruple-mutant allele (D6-PvDHFR). Plasma JPC2056 and JPC2067 concentrations were measured by LC-mass spectrometry. RESULTS: The mean inhibitory dilution (ID(90)) of monkey plasma at 3 h after drug administration against D6, K1 and TM90-C2A was, respectively, 1253, 585 and 869 after the single-dose regimen and 1613, 1120 and 1396 following the multiple-dose regimen. Less activity was observed with the same monkey plasma samples against the D6-PvDHFR line, with a mean ID(90) of 53 after multiple dosing. Geometric mean plasma concentrations of JPC2056 and JPC2067 at 3 h after drug administration were, respectively, 113 and 12 ng/mL after the single dose and 150 and 17 ng/mL after multiple dosing. The mean elimination half-life of JPC2056 was shorter than its metabolite after both regimens (single dose, 7.3 versus 11.8 h; multiple doses, 6.6 versus 11.1 h). CONCLUSIONS: The high potency of JPC2056 against P. falciparum DHFR-TS quadruple-mutant lines provides optimism for the future development of JPC2056 for the treatment of malaria infections.
Subject(s)
Antimalarials/pharmacology , Antimalarials/pharmacokinetics , Animals , Antimalarials/administration & dosage , Antimalarials/blood , Attention , Chromatography, High Pressure Liquid , Drug Resistance, Microbial/genetics , Half-Life , Macaca fascicularis , Male , Mass Spectrometry , Parasitic Sensitivity Tests , Plasma/chemistry , Plasmodium falciparum/drug effects , Plasmodium vivax/drug effectsABSTRACT
WR227825 is an antimalarial pyrroloquinazolinediamine derivative with a high potency but a low therapeutic index. A series of carbamate, carboxamide, succinimide, and alkylamine derivatives of WR227825 were prepared to search for compounds with an improved therapeutic index. The new acetamides and imide showed potent cell growth inhibition against four clones of Plasmodium falciparum (D-6, RCS, W-2, and TM91C235), with a 50% inhibitory concentration of approximately 0.01 ng/ml, and were highly active against Plasmodium berghei, with 100% cure at doses from <0.1 mg/kg of body weight to 220 mg/kg. The carbamates and alkyl derivatives, however, showed weak activity against Plasmodium falciparum cell growth but were highly efficacious in tests against P. berghei by the Thompson test. The best compounds, bis-ethylcarbamate (compound 2a) and tetra-acetamide (3a) derivatives, further demonstrated high potency against the sporozoite Plasmodium yoelii in mice and P. falciparum and Plasmodium vivax in aotus monkeys. Against the AMRU-1 strain of P. vivax, which has four dihydrofolate reductase mutations and is highly resistant to antifolates, tetra-acetamide 3a cured the monkeys at doses of 1 and 3 mg/kg. Compound 2a cured only one out of two monkeys at 3 mg/kg. The results indicated that the new derivatives 2a and 3a not only have retained/improved the antimalarial efficacy of the parent compound WR227825 but also were less toxic to the animals used in the tests.
Subject(s)
Antimalarials/pharmacology , Plasmodium falciparum/drug effects , Pyrroles/chemical synthesis , Pyrroles/pharmacology , Quinazolines/chemical synthesis , Quinazolines/pharmacology , Animals , Antimalarials/adverse effects , Antimalarials/therapeutic use , Disease Models, Animal , Malaria/blood , Malaria/drug therapy , Mice , Plasmodium berghei/drug effects , Pyrroles/therapeutic use , Quinazolines/therapeutic useABSTRACT
WR182393, a guanidinoimidazolidinedione derivatives with potent causal prophylactic antimalarial activity by intramuscular injection, was previously prepared by treatment of chloroproguanil and diethyl oxalate, yielding a mixture of two closely related isomers. Poor solubility of the mixture made the separation and purification impossible. To overcome the separation problem, new and facile unambiguous syntheses of the two active components were reported. The new synthetic methods facilitate the synthesis of not only the active components, but also their derivatives. To search for compounds with good oral efficacy, a series of carbamate derivatives of the active components were prepared by the new procedure, many of which showed profound causal prophylactic antimalarial activity against Plasmodium yoelii in mouse by oral administration.
Subject(s)
Antimalarials/chemical synthesis , Carbamates/chemical synthesis , Imidazolidines/chemical synthesis , Administration, Oral , Animals , Antimalarials/chemistry , Antimalarials/pharmacology , Carbamates/chemistry , Carbamates/pharmacology , Guanidines/chemistry , Imidazoles/chemistry , Imidazolidines/chemistry , Imidazolidines/pharmacology , Malaria/parasitology , Malaria/prevention & control , Male , Mice , Plasmodium falciparum/drug effects , Plasmodium yoelii , Structure-Activity RelationshipABSTRACT
On the basis of earlier reported quantitative structure-activity relationship studies, a series of 9beta-16-(arylalkyl)-10-deoxoartemisinins were proposed for synthesis. Several of the new compounds 7 and 10-14 were synthesized employing the key synthetic intermediate 23. In a second approach, the natural product (+)-artemisinic acid was utilized as an acceptor for conjugate addition, and the resultant homologated acids were subjected to singlet oxygenation and acid treatment to provide artemisinin analogues. Under a new approach, we developed a one step reaction for the interconversion of artemisinin 1 into artemisitene 22 that did not employ selenium-based reagents and found that 2-arylethyliodides would undergo facile radical-induced conjugate addition to the exomethylene lactone of 22 in good yield. The lactone carbonyls were removed sequentially by diisobutylaluminum hydride reduction followed directly by a second reduction (BF(3)-etherate/Et(3)SiH) to afford the desired corresponding pyrans. Six additional halogen-substituted aromatic side chains were installed via 22 furnishing the bioassay candidates 15-20. The analogues were examined for in vitro antimalarial activity in the W-2 and D-6 clones of Plasmodium falciparum and were additionally tested in vivo in Plasmodium berghei- and/or Plasmodium yoelii-infected mice. Several of the compounds emerged as highly potent orally active candidates without obvious toxicity. Of these, two were chosen for pharmacokinetic evaluation, 14 and 17.
Subject(s)
Antimalarials/chemistry , Artemisinins , Sesquiterpenes/chemistry , Administration, Oral , Animals , Antimalarials/chemical synthesis , Antimalarials/pharmacokinetics , Antimalarials/pharmacology , Drug Evaluation, Preclinical , Drug Resistance , Injections, Intravenous , Malaria/drug therapy , Mice , Plasmodium berghei , Plasmodium falciparum/drug effects , Plasmodium yoelii , Rats , Rats, Sprague-Dawley , Sesquiterpenes/chemical synthesis , Sesquiterpenes/pharmacokinetics , Sesquiterpenes/pharmacology , Stereoisomerism , Structure-Activity RelationshipABSTRACT
During June 1996, water supplies of the city of San Pedro Sula, Honduras, were sampled to obtain an assessment of Cryptosporidium oocyst and Guardia cyst concentrations. Each sample was concentrated and stained with an indirect immunofluorescent antibody, and parasites were counted through microscopic analysis. In three surface water supplies, Crytosporidium oocyst concentrations ranged from 58 to 260 oocysts per 100 L, and Giardia cysts were present in concentrations ranging 380 to 2100 cysts per 100 L. Unlike the surface water samples, groundwater acquifer protects the water supply more effectively from larger Giardia cysts. Cryptosporidium oocyst concentrations are within the typical range for surface water supplies in North America whereas Giardia cyst concentrations are elevated. Efforts should be made to protect raw water from sources of contamination (AU)
Subject(s)
Humans , Gastrointestinal Diseases , Honduras , Giardiasis/diagnosis , Giardia lamblia/isolation & purification , Cryptosporidium parvum/pathogenicity , Protozoan Infections/diagnosis , Water Quality/analysisABSTRACT
During June 1996, water supplies of the city of San Pedro Sula, Honduras, were sampled to obtain an assessment of Cryptosporidium oocyst and Giardia cyst concentrations. Each sample was concentrated and stained with an indirect immunofluorescent antibody, and parasites were counted through microscopic analysis. In three surface water supplies, Cryptosporidium oocyst concentrations ranged from 58 to 260 oocysts per 100 L, and Giardia cysts were present in concentrations ranging from 380 to 2 100 cysts per 100 L. Unlike the surface water samples, groundwater had a higher concentration of Cryptosporidium oocysts (26/100 L) than Giardia cysts (6/100 L), suggesting that the groundwater aquifer protects the water supply more effectively from larger Giardia cysts. Cryptosporidium oocyst concentrations are within the typical range for surface water supplies in North America whereas Giardia cyst concentrations are elevated. Efforts should be made to protect raw water from sources of contamination
Subject(s)
Cryptosporidium/isolation & purification , Giardia/isolation & purification , Water Supply/analysis , HondurasABSTRACT
During June 1996, water supplies of the city of San Pedro Sula, Honduras, were sampled to obtain an assessment of Cryptosporidium oocyst and Giardia cyst concentrations. Each sample was concentrated and stained with an indirect immunofluorescent antibody, and parasites were counted through microscopic analysis. In three surface water supplies, Cryptosporidium oocyst concentrations ranged from 58 to 260 oocysts per 100 L, and Giardia cysts were present in concentrations ranging from 380 to 2 100 cysts per 100 L. Unlike the surface water samples, groundwater had a higher concentration of Cryptosporidium oocysts (26/100 L) than Giardia cysts (6/100 L), suggesting that the groundwater aquifer protects the water supply more effectively from larger Giardia cysts. Cryptosporidium oocyst concentrations are within the typical range for surface water supplies in North America whereas Giardia cyst concentrations are elevated. Efforts should be made to protect raw water from sources of contamination
Para estimar las concentraciones de oocistos de Cryptosporidium y quistes de Giardia en los abastecimientos de agua de la ciudad de San Pedro Sula, se examinaron muestras del agua en junio de 1996. Cada muestra se concentró y se marcó con un anticuerpo inmunofluorescente indirecto y los parásitos se contaron mediante análisis microscópico. En tres abatecimientos de agua, las concentraciones de oocistos de Cryptosporidium alcanzaron un recorrido de 58 a 260 oocistos por 100 L, mientras que los quistes de Giardia se encontraron en concentraciones de 380 a 2 100 quistes por 100 L. Al contrario de las muestras de agua superficial, el agua subterránea tuvo mayor concentración de oocistos de Cryptosporidium (26/100 L) que de quistes de Giardia (6/100 L), lo que sugiere que el acuífero subterráneo protege mejor al abastecimiento de agua contra los quistes de Giardia, que son más grandes. Las concentraciones de oocistos de Cryptosporidium estuvieron dentro del recorrido típico de los abastecimientos de agua en Norteamérica, pero los de Giardia fueron más elevados. Deben tomarse medidas para proteger el agua sin depurar de las fuentes de contaminación.
Subject(s)
Cryptosporidium , Giardia , Water Supply/analysis , HondurasABSTRACT
We report on our investigation of a malaria outbreak in Honduras, Central America, in January 1997. We tested 202 patients with fever and chills using thin and thick blood film microscopy. Sixteen patients lived in the city and the rest lived in the rural areas. A total of 95 samples (47 percent) were positive for malaria parasites. Seventy-nine percent (63/80) of the rural patients were infected with Plasmodium vivax and 21 percent (17/80) were infected with P. falciparum. In the urban area, all 15 infected patients had P. vivax malaria and none showed evidence of P. falciparum. Since previous reports inidicate that falciparum malaria accounts for only 2 percent of the overall malaria infections in Honduras, the results reported here suggest that there is a dramatic increase in flaciparum malaria in the area of Honduras investigated in this study (AU)
Subject(s)
Humans , Malaria , Cross-Sectional Studies , Honduras , Malaria, Falciparum/epidemiology , Disease Outbreaks/statistics & numerical dataABSTRACT
We report on our investigation of a malaria outbreak in Honduras, Central America, in January 1997. We tested 202 patients with fever and chills using thin and thick blood film microscopy. Sixteen patients lived in the city and the rest lived in rural areas. A total of 95 samples (47%) were positive for malaria parasites. Seventy-nine percent (63/80) of the rural patients were infected with Plasmodium vivax and 21% (17/80) were infected with P. falciparum. In the urban area, all 15 infected patients had P. vivax malaria and none showed evidence of P. falciparum. Since previous reports indicate that falciparum malaria accounts for only 2% of the overall malaria infections in Honduras, the results reported here suggest that there is a dramatic increase in falciparum malaria in the area of Honduras investigated in this study.
Notificamos los resultados de un estudio de un brote de malaria que se produjo en Honduras, Centroamérica, en enero de 1997. Sometimos a examen microscópico frotis delgados y frotis gruesos de la sangre de 202 pacientes con fiebre y escalofríos. Dieciséis pacientes eran habitantes de la zona urbana y el resto de la zona rural. Un total de 95 especímenes (47%) fueron positivos a parásitos de la malaria. Setenta y ocho por ciento (62/80) de los pacientes del área rural estaban infestados con Plasmodium vivax y 22% (17/80) con P. falciparum. En la zona urbana, todos los 15 pacientes que estaban infestados tenían P. vivax y en ninguno se detectó P. falciparum. Ya que según informes previos la malaria de tipo falciparum representa solamente 2% de todos los casos de malaria en Honduras, nuestros resultados sugieren que hay un gran incremento del número de casos de malaria falciparum en la zona de Honduras en que se llevó a cabo esta investigación.